Stock Price Forecast

May 28, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Zafgen, Inc. chart...

About the Company

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Sector

Health Technology

Industry

Biotechnology

Employees

7

CEO

Jeffrey S. Hatfield

Exchange

NASDAQ

Website

http://www.zafgen.com

$M

Total Revenue

7

Employees

$37M

Market Capitalization

-1.02

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ZFGN News

Zafgen Enters Oversold Territory

1y ago, source: AOL

Zafgen, Inc. ZFGN has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when ...

Buy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug Nomlabofusp

13d ago, source:

Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Larimar Therapeutics (LRMR – Research Report), with a price ...

Buy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s Ataxia

17d ago, source:

LifeSci Capital analyst Cory Jubinville, PhD has maintained their bullish stance on LRMR stock, giving a Buy rating today. Cory Jubinville, ...

Zenas BioPharma Appoints Patricia Allen to its Board of Directors

23d ago, source: Morningstar

Prior to Vividion, Ms. Allen was the Chief Financial Officer at Zafgen, Inc. (now Larimer Therapeutics). Earlier, she was Vice President of Finance and Treasurer, Principal Financial Officer of ...

Jeffrey S. Hatfield's Net Worth

1mon ago, source: Benzinga.com

Who is Jeffrey S. Hatfield? Jeffrey S. Hatfield has an estimated net worth of $8.3 Million. This is based on reported shares across multiple companies, which include Viridian Therapeutics, Inc.\DE ...

Sweet Baby Inc. Doesn’t Do What Some Gamers Think It Does

23d ago, source: Kotaku

Sweet Baby Inc. is not the largest narrative design company in the games industry. Nor is it solely responsible for the characters and stories in recent high-profile releases like Alan Wake 2 ...

Larimar Therapeutics Inc (LRMR) Earnings Dates & Reports

15d ago, source: Investing

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Snap Inc Class A

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Welcome to Inc.'s Directory of B2B Excellence

5mon ago, source: Inc

They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.

Starwood Property Trust Inc.

1d ago, source: MarketWatch

Annaly Capital Management Inc. 6.5% Conv. Pfd. Series G 0.44% Annaly Capital Management Inc. Pfd. Series I 0.32% Annaly Capital Management Inc. 6.95% Cum. Redeem. Pfd. Series F 0.48% ...

STIHL Inc.

7mon ago, source: Forbes

This company has paid to receive expanded profile features. About STIHL Inc. Virginia-based STIHL Inc. is the U.S. affiliate for the global STIHL group and the manufacturer of the number one ...

Zenas BioPharma Appoints Patricia Allen to its Board of Directors

23d ago, source: Yahoo Finance

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...